Cargando…
Tumour suppressor EP300, a modulator of paclitaxel resistance and stemness, is downregulated in metaplastic breast cancer
PURPOSE: We have previously described a novel pathway controlling drug resistance, epithelial-to-mesenchymal transition (EMT) and stemness in breast cancer cells. Upstream in the pathway, three miRs (miR-106b, miR-93 and miR-25) target EP300, a transcriptional activator of E-cadherin. Upregulation o...
Autores principales: | Asaduzzaman, Muhammad, Constantinou, Stephanie, Min, Haoxiang, Gallon, John, Lin, Meng-Lay, Singh, Poonam, Raguz, Selina, Ali, Simak, Shousha, Sami, Coombes, R. Charles, Lam, Eric W.-F., Hu, Yunhui, Yagüe, Ernesto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5427146/ https://www.ncbi.nlm.nih.gov/pubmed/28341962 http://dx.doi.org/10.1007/s10549-017-4202-z |
Ejemplares similares
-
FOXA1 is a determinant of drug resistance in breast cancer cells
por: Kumar, Uttom, et al.
Publicado: (2021) -
The mixed subtype has a worse prognosis than other histological subtypes: a retrospective analysis of 217 patients with metaplastic breast cancer
por: Hu, Jiayue, et al.
Publicado: (2023) -
Paclitaxel in self-micro emulsifying formulations: oral bioavailability study in mice
por: Oostendorp, Roos L., et al.
Publicado: (2010) -
Chidamide combined with paclitaxel effectively reverses the expression of histone deacetylase in lung cancer
por: Zhang, Na, et al.
Publicado: (2020) -
Paclitaxel Drug-Coated Balloon Angioplasty Suppresses Progression and Inflammation of Experimental Atherosclerosis in Rabbits
por: Chowdhury, Mohammed M., et al.
Publicado: (2020)